Risk of recurrent ischemic stroke in patients with patent foramen ovale: The role of D-dimer

被引:2
作者
Park, Seongho [1 ]
Kwon, Boseong [2 ]
Oh, Jin Kyung [3 ]
Song, Jae-Kwan [4 ]
Lee, Ji Sung [5 ]
Kwon, Sun U. [6 ]
机构
[1] Inje Univ, Haeundae Paik Hosp, Dept Neurol, Coll Med, Busan, South Korea
[2] Univ Ulsan, Asan Med Ctr, Dept Radiol, Coll Med, Seoul, South Korea
[3] Chungnam Natl Univ, Sejong Chungnam Natl Univ Hosp, Dept Internal Med, Div Cardiol,Coll Med, Daejeon, South Korea
[4] Univ Ulsan, Asan Med Ctr, Dept Cardiol, Coll Med, Seoul, South Korea
[5] Univ Ulsan, Asan Inst Life Sci, Clin Res Ctr,Coll Med, Asan Med Ctr, Seoul, South Korea
[6] Univ Ulsan, Asan Med Ctr, Dept Neurol, Coll Med, 88,Olympic Ro 43 Gil, Seoul 05505, South Korea
关键词
D-dimer; PFO; Recurrent ischemic stroke; Hypercoagulable state; CRYPTOGENIC STROKE; CLOSURE; THERAPY;
D O I
10.1016/j.jstrokecerebrovasdis.2023.107246
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Paradoxical embolism under elevated thromboembolic conditions is known to be the primary mechanism of patent foramen ovale (PFO)-related stroke. We hypothesized that higher levels of D-dimer, a marker of thromboembolism, could increase the risk of stroke recurrence in patients with PFO. Methods: We conducted a retrospective analysis of data from 1226 consecutive patients with acute ischemic cryptogenic stroke (CS) who underwent transesophageal echocardiography (TEE). D-dimer was assessed during admission. We used a multivariate Cox proportional hazards model to evaluate the association of long-term outcomes between the presence of PFO and levels of D-dimer. Results: Of the 1226 patients, the study included 461 who underwent TEE. Among them, 242 (52.5%) had PFOs. Among PFO patients, those with a D-dimer level >1.0 mg/L had a significantly higher risk of stroke recurrence compared to those with <0.5mg/L (adjusted hazard ratio (aHR) 4.04, 95% confidence interval [CI] 1.63-10.02). A pattern of increased risk of event with increasing D-dimer levels was observed (Ptrend=0.008). However, there was no significant difference in the risk of stroke recurrence at any D-dimer level compared to D-dimer level <0.5 mg/L among patients without PFO. In these patients, there was little evidence of increased risk with increasing Ddimer levels (Ptrend=0.570). Conclusions: This study demonstrated that the elevated D-dimer level increased the recurrence of stroke in CS patients with PFO, particularly showing a dose-dependent relationship between D-dimer levels and recurrence. However, no such effect was observed in patients without PFO. These findings provide valuable insights into the potential benefits of anticoagulation for strokes related to PFO.
引用
收藏
页数:6
相关论文
共 27 条
[1]   Recurrent cerebral ischemia in medically treated patent foramen ovale A meta-analysis [J].
Almekhlafi, M. A. ;
Wilton, S. B. ;
Rabi, D. M. ;
Ghali, W. A. ;
Lorenzetti, D. L. ;
Hill, M. D. .
NEUROLOGY, 2009, 73 (02) :89-97
[2]   Patent Foramen Ovate and Stroke-Current Status [J].
Bang, Oh Young ;
Lee, Mi Ji ;
Ryoo, Sookyung ;
Kim, Suk Jae ;
Kim, Ji Won .
JOURNAL OF STROKE, 2015, 17 (03) :229-237
[3]   Coagulation abnormalities in adults with cryptogenic stroke and patent foramen ovale [J].
Chaturvedi, S .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 160 (02) :158-160
[4]   d-dimer Level as a Predictor of Recurrent Stroke in Patients With Embolic Stroke of Undetermined Source [J].
Choi, Kang-Ho ;
Kim, Ja-Hae ;
Kim, Jae-Myung ;
Kang, Kyung-Wook ;
Lee, Changho ;
Kim, Joon-Tae ;
Choi, Seong-Min ;
Park, Man-Seok ;
Cho, Ki-Hyun .
STROKE, 2021, 52 (07) :2292-2301
[5]   Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study [J].
Cosmi, Benilde ;
Legnani, Cristina ;
Tosetto, Alberto ;
Pengo, Vittorio ;
Ghirarduzzi, Angelo ;
Alatri, Adriano ;
Prisco, Domenico ;
Poli, Daniela ;
Tripodi, Armando ;
Palareti, Gualtiero .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2009, 28 (04) :381-388
[6]   Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence [J].
Danese, Elisa ;
Montagnana, Martina ;
Cervellin, Gianfranco ;
Lippi, Giuseppe .
ANNALS OF MEDICINE, 2014, 46 (06) :364-371
[7]   Patent foramen ovale and the risk of ischemic stroke in a multiethnic population [J].
Di Tullio, Marco R. ;
Sacco, Ralph L. ;
Sciacca, Robert R. ;
Jin, Zhezhen ;
Homma, Shunichi .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (07) :797-802
[8]   Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA [J].
Dia, AbdulRahman ;
Cifu, Adam S. ;
Shah, Atman P. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (01) :81-82
[9]   Executive Summary Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Guyatt, Gordon H. ;
Akl, Elie A. ;
Crowther, Mark ;
Gutterman, David D. ;
Schuenemann, Holger J. .
CHEST, 2012, 141 (02) :7S-47S
[10]   Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial [J].
Kasner, Scott E. ;
Swaminathan, Balakumar ;
Lavados, Pablo ;
Sharma, Mukul ;
Muir, Keith ;
Veltkamp, Roland ;
Ameriso, Sebastian F. ;
Endres, Matthias ;
Lutsep, Helmi ;
Messe, Steven R. ;
Spence, J. David ;
Nedeltechev, Krassen ;
Perera, Kanjana ;
Santo, Gustavo ;
Olavarria, Veronica ;
Lindgren, Arne ;
Shoamanesh, Ashkan ;
Berkowit, Scott D. ;
Mundt, Nardi ;
Connolly, Stuart ;
Hart, Robert G. .
LANCET NEUROLOGY, 2018, 17 (12) :1053-1060